Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.
Other share classesSLXN
13F holders, Q1 2026
Institutional positions in Silexion Therapeutics Corp as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −3 vs. Q4 2025
- Shares held
- 2.34M
- −31.8K (−1.3%) vs. Q4 2025
- Total value
- $47.7K
- −$14.0K (−22.7%) vs. Q4 2025
- New holders
- 0
- 1 more added
- Sold out
- 3
- 1 more reduced
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLXNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $70.3K |
| Q1 2026 | 19 | $47.7K |
| Q4 2025 | 22 | $61.8K |
| Q3 2025 | 22 | $89.8K |
| Q2 2025 | 22 | $107.6K |
| Q1 2025 | 25 | $199.1K |
| Q4 2024 | 26 | $91.7K |
| Q3 2024 | 32 | $106.1K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Saba Capital Management, L.P. | 11,937 | $242 | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 16,000 | $325 | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 32,500 | $406 | 0.00% | 00.0% | Unchanged |
| Gabelli Funds LLC | 30,496 | $619 | 0.00% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 31,552 | $641 | 0.00% | 00.0% | Unchanged |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $774 | 0.00% | 00.0% | Unchanged |
| Mint Tower Capital Management B.V. | 25,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 50,000 | $1.01K | 0.00% | 00.0% | Unchanged |
| Context Capital Management, LLC | 51,183 | $1.04K | 0.00% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 57,175 | $1.16K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 74,910 | $1.52K | 0.00% | 00.0% | Unchanged |
| Security Benefit Life Insurance Co | 150,000 | $1.88K | 0.00% | 00.0% | Unchanged |
| Kepos Capital LP | 100,000 | $2.00K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 123,494 | $2.51K | 0.00% | +2,257+1.9% | Added |
| Clear Street Group Inc. | 218,765 | $4.44K | 0.00% | −200−0.1% | Reduced |
| Aristeia Capital LLC | 236,546 | $5.05K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 337,500 | $7.22K | 0.00% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 743,475 | $15.9K | 0.00% | 00.0% | Unchanged |
| Oasis Management Co Ltd. | 11,111 | – | – | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −21,260−100.0% | Sold out |